$MIRO News

Last published 2y ago

2y agoMIRO UTHRUnited Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and MergerBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has
2y agoMIRO UTHRUnited Therapeutics and Miromatrix Medical Announce Successful Tender OfferBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned
2y agoMIRO UTHRMiromatrix Reports Third Quarter 2023 ResultsGlobeNewswireEDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help
3y agoBBAI BVH MIRO SIXMoore Kuehn Encourages BBAI, SIX, MIRO, and BVH Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoSRC MIRO DOC SIXMoore Kuehn Encourages SRC, MIRO, DOC, and SIX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
3y agoMIROUnited Therapeutics to Acquire Miromatrix MedicalGlobeNewswireSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a
3y agoMIRO UTHRUnited Therapeutics to Acquire Miromatrix MedicalBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company
3y agoMIROMiromatrix to Present at the 2023 ISODP Organ Donation CongressGlobeNewswireEDEN PRAIRIE, Minn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the MesaGlobeNewswireEDEN PRAIRIE, Minn., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Announces Participation in H.C. Wainwright Global Investment ConferenceGlobeNewswireEDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics WorkshopGlobeNewswireEDEN PRAIRIE, Minn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Medical Inc. (MIRO) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoMIROMiromatrix Reports Second Quarter 2023 Results and Provides Corporate UpdateGlobeNewswireEDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix to Report Second Quarter 2023 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement AwardGlobeNewswireEDEN PRAIRIE, Minn., July 13, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Announces CEO Jeff Ross, Ph.D. will Expand His Role by Resuming Leadership of R&DGlobeNewswireEDEN PRAIRIE, Minn., June 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Presenting at the 2023 American Transplant CongressGlobeNewswireEDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve
3y agoMIROMiromatrix Announces Participation in the 20th Annual Craig-Hallum Institutional Investor ConferenceGlobeNewswireEDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve
3y agoMIROMiromatrix Reports First Quarter 2023 Results and Provides Corporate UpdateGlobeNewswireEDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve
3y agoMIROMiromatrix to Report First Quarter 2023 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the MedGlobeNewswireEDEN PRAIRIE, Minn., April 10, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoCDNA MIROCareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human TransplantationBusiness WireCareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials Companies at Forefront of Alternative Organ Supply Research to Address Organ Shortage CareDx, Inc. (NASDAQ:CDNA) and
3y agoCDNA MIROCareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human TransplantationGlobeNewswireCareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials Companies at Forefront of Alternative Organ Supply Research to Address Organ Shortage BRISBANE, Calif. and EDEN PRAIRIE,
3y agoMIROMiromatrix Reports Fourth Quarter and Full Year 2022 Results and Provides Corporate UpdateGlobeNewswireEDEN PRAIRIE, Minn., March 31, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix to Report Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., March 15, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Medical Inc. Announces Pricing of $10 Million Public Offering of Common StockGlobeNewswireEDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. ("Miromatrix") (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help
3y agoMIROMiromatrix Medical Inc. Announces Proposed Public Offering of Common StockGlobeNewswireEDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. ("Miromatrix") (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help
3y agoBAX MIROMiromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver FailureGlobeNewswireCombines Miromatrix's expertise in bioengineered organs with Baxter's leadership in critical care delivery and organ support therapiesIncludes intended Phase I clinical trial designed to generate key evidence to support
3y agoBAX MIROMiromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver FailureBusiness WireCombines Miromatrix's expertise in bioengineered organs with Baxter's leadership in critical care delivery and organ support therapies Includes intended Phase I clinical trial designed to generate key evidence to
3y agoMIROMiromatrix Provides Update on miroliverELAPGlobeNewswireEDEN PRAIRIE, Minn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoAXGN MIRO VRAYViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial OfficerPR NewswireDENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary
3y agoMIROMiromatrix Announces FDA Clinical Hold on IND Application for miroliverELAPGlobeNewswireEDEN PRAIRIE, Minn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Announces Participation in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewswireEDEN PRAIRIE, Minn., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
3y agoMIROMiromatrix Reports Filing of IND, Third Quarter 2022 Results, and Provides Corporate UpdateGlobeNewswireEDEN PRAIRIE, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
4y agoMIROMiromatrix to Report Third Quarter 2022 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
4y agoMIROMiromatrix CEO Jeff Ross Delivering Keynote Address at ARMI | BioFabUSA 2022 Fall Summit: Meeting in the MillyardGlobeNewswireEDEN PRAIRIE, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and
4y agoMIROMiromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the MesaGlobeNewswireEDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced
4y agoMIROMiromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual EventGlobeNewswireEDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announce
4y agoMIROMiromatrix CEO Jeff Ross to Present at the Bioregate European Regenerative Medicine ForumGlobeNewswireEDEN PRAIRIE, Minn., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announce
4y agoMIROMiromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization TechnologyGlobeNewswireEDEN PRAIRIE, Minn., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a
4y agoMIROMiromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company ShowcaseGlobeNewswireEDEN PRAIRIE, Minn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced
4y agoMIROMiromatrix Reports Second Quarter 2022 Results and Provides Corporate UpdateGlobeNewswireEDEN PRAIRIE, Minn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported
4y agoMIROMiromatrix Appoints Jack Lake, M.D., as Medical DirectorGlobeNewswireEDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today
4y agoMIROMiromatrix to Report Second Quarter 2022 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced
4y agoMIROMiromatrix Applauds the FDA for Its Continued Commitment to the Field of Organ TransplantGlobeNewswireEDEN PRAIRIE, Minn., July 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, applauds the U.
4y agoMIROMiromatrix Announces Participation in the 2022 American Transplant CongressGlobeNewswireEDEN PRAIRIE, Minn., May 31, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its pa
4y agoMIROMiromatrix Announces Participation in the 19th Annual Craig-Hallum Institutional Investor ConferenceGlobeNewswireEDEN PRAIRIE, Minn., May 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that m
4y agoMIROMiromatrix Announces Participation in H.C. Wainwright Global Investment ConferenceGlobeNewswireEDEN PRAIRIE, Minn., May 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its pa
4y agoMIROMiromatrix Reports First Quarter 2022 Results and Provides Corporate UpdateGlobeNewswireEDEN PRAIRIE, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported f
4y agoMIROMiromatrix to Report First Quarter 2022 Financial ResultsGlobeNewswireEDEN PRAIRIE, Minn., April 28, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announce